论文部分内容阅读
目的利用HepG2.2.2.15细胞模型研究小分子干扰核糖核酸脂质体对乙型肝炎病毒(HBV)的抑制作用。方法在药物对细胞的最大无毒浓度下,依次设定4个浓度梯度,分别测定不同时间收集的培养液中的乙型表面抗原(HBsAg)和乙肝病毒脱氧核糖核酸(HBV-DNA)。结果第12天时质量浓度为5μg/mL的药物对HBV的HBsAg表达的抑制率达到了63%,抑制程度随药物质量浓度的升高,或时间的增加而提高;药物质量浓度为5μg/mL时对HBV-DNA的抑制率达到了85.46%,抑制程度随着药物质量浓度的上升而提高。结论药物对HBV的HBsAg表达的抑制作用具有明显的剂量效应和时间效应,对HBV-DNA的抑制作用也有很好的剂量效应;利用基因工程手段制备的双链小分子RNA脂质体制剂具有明显抑制HBV的HBsAg表达和抑制HBV-DNA复制的作用,为利用RNA干扰技术研究开发新型抗HBV药物创造了条件。
OBJECTIVE: To study the inhibitory effect of small interfering RNA (siRNA) liposomes on Hepatitis B virus (HBV) in HepG2.2.2.15 cell model. Methods Four concentration gradients were set in succession under the maximum non-toxic concentration of the drug. The surface antigen (HBsAg) and HBV-DNA in the culture fluid collected at different time were measured respectively. Results On the 12th day, the drug with the concentration of 5μg / mL had an inhibitory rate of 63% on the HBsAg expression in HBV. The inhibition rate increased with the increase of the drug concentration or the time. When the drug concentration was 5μg / mL The inhibitory rate of HBV-DNA reached 85.46%, the inhibition increased with the increase of drug concentration. Conclusion The drug has obvious dose-effect and time effect on the inhibition of HBV HBsAg expression, and also has a good dose-effect on the inhibition of HBV-DNA. The double-stranded small molecule RNA liposome preparation prepared by genetic engineering has obvious Inhibition of HBV HBsAg expression and inhibition of HBV-DNA replication, for the use of RNA interference technology to develop new anti-HBV drugs to create the conditions.